138274-14-3

Usage

Uses

Used in Pharmaceutical Industry:
2-Chloro-5-(phenylmethoxy)-pyrimidine is used as a building block for the synthesis of various pharmaceuticals. Its unique structure allows for the development of biologically active molecules, contributing to the creation of new compounds with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 2-Chloro-5-(phenylmethoxy)-pyrimidine serves as a key component in the synthesis of agrochemicals. Its incorporation into these products enhances their effectiveness in protecting crops and managing pests.
Used as a Reagent in Organic Chemistry Reactions:
2-Chloro-5-(phenylmethoxy)-pyrimidine is also utilized as a reagent in organic chemistry, facilitating various chemical reactions and transformations. Its presence can influence the outcome of these reactions, making it a valuable tool for researchers and chemists in their quest to develop new compounds and materials.

InChI:InChI=1/C11H9ClN2O/c12-11-13-6-10(7-14-11)15-8-9-4-2-1-3-5-9/h1-7H,8H2

Upstream product

• 100-39-0 benzyl bromide 
• 4983-28-2 2-chloropyrimidine-5-ol 
• 100-44-7 benzyl chloride 

Downstream Products

• 87789-61-5 1-(5-Benzyloxy-2-pyrimidinyl)piperazine 
• 1350730-13-0 5-[5-(benzyloxy)pyrimidin-2-ylamino]-2-fluoro-benzonitrile 

Relevant academic research and scientific papers

SMALL MOLECULE FURIN INHIBITORS FOR TREATING INFECTIOUS DISEASES

Provided herein are methods of treating a viral infection in a subject in need thereof, comprising administering to the subject a compound of Formula (I), or a pharmaceutical composition comprising Formula (I). Further provided herein are methods for inhibiting the replication of a virus (e.g., a togaviridae family virus (e.g., an alphavirus (e.g., Chikungunya virus, Eastern equine encephalitis, Mayaro virus, Venezuelan equine encephalitis virus, Western equine encephalitis)), a filoviradae family virus (e.g., a Marburg virus (e.g., Marburg virus, Ravn virus)), human respiratory syncytial virus (i.e., human orthopneumo viru s ), a flavivirus (e.g., dengue virus, Usutu virus, Japanese encephalitis virus, Powassan virus, yellow fever), a paramyxoviridae family virus (e.g., an orthoparamyxovirinae virus (e.g., a henipavims (e.g., Nipah virus), a morbillivims (e.g., measles morbillivirus))) in a subject in need thereof. Also provided herein are methods for treating and/or preventing a disorder due to a microbial toxin (e.g., due to P. aeruginosa exotoxin A, Clostridium septicum alpha-toxin, diphtheria toxin(s), shiga toxin(s)) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I), or a pharmaceutical composition comprising a compound of Formula (I) as described herein. Also provided are pharmaceutical compositions and kits including a compound of Formula (I) for use in the treatment and/or prevention of a viral infection in a subject in need thereof.

USE OF PYRIDYLOXYPYRIMIDINES FOR TREATING INFECTIOUS DISEASES

Provided herein are methods of treating a viral infection in a subject in need thereof, comprising administering to the subject a compound of Formula (I), or a pharmaceutical composition comprising Formula (I). Further provided herein are methods for inhibiting the replication of a virus (e.g., a togaviridae family virus (e.g., an alphavirus (e.g., Chikungunya virus, eastern equine encephalitis, mayaro virus, Venezuelan equine encephalitis virus, western equine encephalitis)), a filoviradae family virus (e.g., a Marburgvirus (e.g., Marburg virus, Ravn virus)), human respiratory syncytial virus (i.e., human orthopneumo virus ), a flavivirus (e.g., dengue virus, Usutu virus, Japanese encephalitis virus, Powassan virus, yellow fever), a paramyxoviridae family virus (e.g., an orthoparamyxovirinae virus (e.g., a henipavims (e.g., Nipah virus), a morbillivims (e.g., measles morbillivirus))) in a subject in need thereof. Also provided herein are methods for treating and/or preventing a disorder due to a microbial toxin (e.g., due to P. aeruginosa exotoxin A, Clostridium septicum alpha-toxin, diphtheria toxin(s), shiga toxin(s)) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I), or a pharmaceutical composition comprising a compound of Formula (I) as described herein. Also provided are pharmaceutical compositions and kits including a compound of Formula (I) for use in the treatment and/or prevention of a viral infection in a subject in need thereof.

Amine compound inhibiting SSAO/VAP-1 and application thereof in medicine

The invention relates to an amine compound for inhibiting semicarbazide-sensitive amine oxidase (SSAO) and/or vascular adhesion protein 1 (VAP-1) and medicinal application thereof, and further relatesto a pharmaceutical composition containing the compound

Orally Bioavailable Metal Chelators and Radical Scavengers: Multifunctional Antioxidants for the Coadjutant Treatment of Neurodegenerative Diseases

Neurodegenerative diseases are associated with oxidative stress that is induced by the presence of reactive oxygen species and the abnormal cellular accumulation of transition metals. Here, a new series of orally bioavailable multifunctional antioxidants (MFAO-2s) possessing a 2-diacetylamino-5-hydroxypyrimidine moiety is described. These MFAO-2s demonstrate both free radical and metal attenuating properties that are similar to the original published MFAO-1s that are based on 1-N,N′-dimethylsulfamoyl-1-4-(2-pyrimidyl)piperazine. Oral bioavailability studies in C57BL/6 mice demonstrate that the MFAO-2s accumulate in the brain at significantly higher levels than the MFAO-1s while achieving similar neural retina levels. The MFAO-2s protect human neuroblastoma and retinal pigmented epithelial cells against hydroxyl radicals in a dose-dependent manner by maintaining cell viability and intracellular glutathione levels. The MFAO-2s outperform clioquinol, a metal attenuator that has been investigated for the treatment of Alzheimer's disease.

NEUROPROTECTIVE MULTIFUNCTIONAL ANTIOXIDANTS AND THEIR MONOFUNCTIONAL ANALOGS

The neuroprotective multifunctional antioxidants are compounds that contain a 2-diacetylamino-5-hydroxypyrimidine moiety, having the structural formula: wherein R1 is CH2 or C2H4; R2 is H or —OR4 where R4 is H or aryl; and R3a and R3b are independently selected from the group consisting of H and —O-alkyl. The antioxidants are orally bioavailable metal-attenuating multifunctional antioxidants that can independently attenuate transition metals, as well as scavenger free radicals. The multifunctional antioxidant compounds, by their ability to independently chelate metals, such as Fe, Cu or Zn, and scavenge free radicals generated from different sources, are neuroprotective and are beneficial for the treatment of various neurological disorders, such as Alzheimer's disease, Parkinson's disease, ALS, traumatic brain injury, ocular disorders, such as cataract, glaucoma, age-related macular degeneration and other retinal degeneration, as well as for reducing the progression of diabetic complications.

CYCLOAMINO DERIVATIVES AS GPR119 ANTAGONISTS

Therapeutic compounds are disclosed having the general formula (I) that are useful for the treatment of metabolic disorders, including type II diabetes. The compounds have activity as agonists of GPR119. Compounds having the stereochemistry of formula (la) may also demonstrate DPP-IV inhibitory activity.

Synthesis and anxiolytic activity of N-substituted cyclic imides (1R*,2S*3R*,4S*)-N-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-2,3-b icyclo[2.2.1]heptanedicarboxime (Tandospirone) and related compounds

A series of cyclic imides bearing a ω-(4-aryl and 4-heteroaryl-1-piperazinyl)alkyl moieties was synthesized and tested in vivo for anxiolytic activity. The in vitro binding affinities of these compounds were also examined for 5-HT(1A) receptor sites. Structure-activity relationships within these series are discussed. One of these compounds, (1R*,2S*,3R*,4S*)-N-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-2,3- bicyclo[2.2.1]heptanedicarboximide (1: tandospirone), was found to be equipotent with buspirone in its anxiolytic activity and more anxio-selective than buspirone and diazepam. Tandospirone (1) is currently undergoing clinical evaluation as a selective anxiolytic agent.